{"entity":{"id":"nct06120491","kind":"trial","name":"Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents","aka":["EvoPAR-Prostate01"],"tldr":"This study tests a PARP inhibitor; the registry reports that it is active not recruiting.","summary":"The registry lists NCT06120491 as active not recruiting, last updated 2026-07-29. Enrolment is 1898 actual participants. Interventions: Saruparib, Placebo, Abiraterone Acetate, Darolutamide, Enzalutamide. Primary measures include Radiographic Progression-Free Survival (rPFS). No results are posted in the registry; this does not exclude separate publications.","status":"active","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06120491","url":"https://clinicaltrials.gov/study/NCT06120491"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mhspc"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["saruparib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06120491","phase":"3","setting":"A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)","sponsor":"AstraZeneca","participation":[{"nct":"NCT06120491","source":"https://clinicaltrials.gov/study/NCT06120491","fetchedAt":"2026-10-07T16:54:14.819Z","studySha256":"e21aebf40770e6db10f6a23a60d976e44ccec33d8ce5245e0763f068258ee520","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-07-29","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"130 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":1898,"enrolmentType":"ACTUAL","siteCount":322,"recruitingSiteCount":0,"countries":["Australia","Austria","Belgium","Brazil","Canada","Chile","China","France","Germany","Hungary","India","Italy","Japan","Malaysia","Netherlands","Peru","Poland","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2023-11-21","startedType":"actual","enrolled":1898,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06120491/","neighbours":{"cancer":[{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}